As the years roll on, CES continues to be a platform for unveiling state-of-the-art medical technology aimed at addressing long-standing health challenges. The year 2025 marked a turning point for regenerative medicine. During a captivating panel discussion at CES 2025, Jason Haider, CEO of Xenco Medical, and Veerle Dhaenens, general manager at Global Therapy Innovations for Terumo BCT, articulated the notion that we are at a significant “inflection point” — a juncture where diverse technological disciplines have converged and can collaborate effectively.
Haider referenced a “1965 moment” during the discussion, alluding to the year Gordon Moore introduced Moore’s Law. This principle suggested that the number of transistors on computer chips doubles approximately every two years, serving as a metaphor for the rate of technological advancement, which later paved the way for a semiconductor revolution.
Haider believes that regenerative medicine is experiencing a similar pivotal moment. Advances in artificial intelligence, enhanced computer simulations, 3D printing, and a deeper comprehension of medical science—including gene editing and protein folding—have combined to accomplish feats that were once deemed unattainable.
Xenco Medical’s goal is to “calibrate” regeneration by carefully providing just the right amount of biomaterials—substances essential for guiding the body back to its natural state. This measured approach aims to minimize potential side effects, such as unintended bone growth.
Moreover, the company aspires to “cascade” regeneration. This strategy will enable the body to exceed its typical healing mechanisms. Xenco plans to equip surgeons with a variety of implants that differ in density and growth factors, ensuring each patient receives the most suitable option for their needs.
These advancements promise two transformative outcomes for the general public: the potential for more cost-effective treatments and enhanced medical accessibility over the next five to ten years, all while boosting the effectiveness of those treatments.
According to Xenco, the rise of in silico trials—computer-based simulations revealing how a drug or illness might impact an individual’s body—is central to the future of medicine. The FDA has indicated in a report that such trials are an inexorable trend, and advancements in AI technology will expedite growth in this arena.
Dhaenens highlighted that artificial intelligence could enhance the success rates of specific procedures dramatically, improving from 47% to 92%—a remarkable increase.
Both experts also discussed the COVID-19 pandemic, noting that while it was a tragic event, the rapid global response has been instrumental in propelling advancements in medical technology.
